Preventing virus infections in newborns
Scientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2158 entries already.
Entries by Thomas Gabrielczyk
Evotec and Indivumed join forces in CRC
Evotec SE and Indivumed GmbH have entered into a drug R&D collaboration aimed at developing first-in-class colorectal cancer treatments.
Inhibitor-free DNA Reliability for any Throughput
BioEcho develops single-spin and 96-well kits for the isolation of DNA. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents resulting in increased sensitivity and reliability of downstream analyses. Therefore, the risk of inhibition or complete failure of PCR applications is eliminated. The process does not require washing steps and is significantly faster than commonly used bind-wash-elute methods.
Theranexus colloborates with AI expert Dyliss
Lyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and Sequences).
uniQure Receives FDA Fast Track Designation for AMT-130
Following the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntington’s Disease gene therapy in Q2/2019.
Sanofi ends option phase of rare disease partnership with Alnylam
Sanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases.
Medigene AG in potential €1bn licence and R&D deal
Roivant Sciences and Sinovant Sciences have launched newco Cytovant Sciences, which licenced two T cell-based cancer immune therapies and two development programmes from Medigene AG for commercialisation in the eastern Asian market.
AMR diagnostic specialist Gradientech raise $4.6m
Gradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST).
Reaching global markets
Small- and medium-size European companies face the challenge of establishing global B2B activities in order to access relevant markets along the drug development value chain. YUMAB’s flexible business model for the development of fully human antibodies attracts corporations overseas and facilitates international partnerships.
AgomAb Therapeutics bags €21m Series A financing
AgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a €21m Series A financing.